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Short bowel syndrome and severe skin 
toxicity as a complication of FOLFOX 
chemotherapy with panitumumab  
in a patient with colorectal cancer  
— a case report
ABSTRACT
The combination of monoclonal antibodies targeting epidermal growth factor receptor (EGFR) with chemotherapy 
is the standard treatment in advanced colorectal cancer without mutations in the RAS and BRAF genes. We pre-
sent a case of a 55-year-old female patient with unacceptable skin toxicity and short bowel syndrome caused by 
palliative FOLFOX chemotherapy combined with panitumumab. In 2012, after the emergence of an artificial anus 
due to gastrointestinal obstruction in the course of rectal cancer, the patient underwent inductive chemotherapy, 
preoperative chemoradiotherapy, and radical surgery. Tubular adenocarcinoma G2, ypT2N0 was diagnosed. In 
2013 and 2015 she underwent two additional surgeries including intestinal resection due to obstruction of the 
gastrointestinal tract and enterovaginal fistula. In February 2018 she was qualified for palliative chemotherapy 
because of inoperable relapse. Due to very good performance status (PS0) and absence of mutations of RAS 
and BRAF genes, regardless of being underweight and suffering from loose stools persisting from the time of 
surgery, FOLFOX chemotherapy with panitumumab was introduced. After the second administration of drugs an 
acne-like rash, hand-foot syndrome, and diarrhoea appeared. Intensification of symptoms and manifestations of 
short bowel syndrome were observed afterwards. Topical treatment of skin lesions, doxycycline, and anti-diarrhoeal 
therapy were introduced, with a mediocre therapeutic effect. Imaging confirmed disease stabilisation, but due 
to the deterioration of both performance status and life quality, anti-cancer treatment was discontinued. This 
case draws attention to the necessity of caution while qualifying for potentially toxic combination chemotherapy.
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Introduction
The occurrence of colorectal cancer (CRC) is steadily 
increasing, making it the third most common malignancy 
in the world and the second one in Europe [1]. According 
to data from Surveillance, Epidemiology, and End Results 
(SEER) colorectal cancer is disseminated in 22% of pa-
tients during the diagnosis [2]. In addition, about 30–40% 
of patients in stage III will relapse within five years.
The main treatment method for disseminated CRC 
is chemotherapy and targeted therapy. The percentage 
of five-year overall survival (OS) in this group of patients 
in western countries reaches 14%, which is probably 
primarily the result of radical surgery in oligometa-
static disease (metastasectomy). The median survival 
for patients receiving fluoropyrimidine, oxaliplatin and 
irinotecan-based sequential palliative chemotherapy is 
about 20 months.
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The addition of molecular targeted drugs to the 
standard mentioned above contributes to the improve-
ment in the treatment results. In cancer cells, about half 
of patients have activating mutations of the KRAS (exons 
2, 3, 4) and NRAS genes (exons 2, 3, 4), and about 10% in 
the BRAF gene [3–5]. These are negative predictors for 
efficacy of treatment with panitumumab and cetuximab, 
which are both anti-EGFR (epidermal growth factor 
receptor) monoclonal antibodies. These medications 
can be used in mutations-negative patients. Despite 
different antibody isotypes (panitumumab — IgG2 and 
cetuximab — IgG1), no differences in their effectiveness 
were demonstrated [6].
Initially, the benefit from using anti-EGFR antibod-
ies in the third-line therapy was demonstrated in patients 
with wild-type KRAS tumours — in monotherapy the re-
sponse was observed in 13% of patients, and the median 
OS increased from 4.8 months to 9.5 months compared 
with best supportive care [7]. Studies assessing the com-
bination of antibodies with first-line chemotherapy not 
only showed a positive effect on life extension of such 
treatment, but also enabled the determination of further 
negative predictive factors as KRAS as well as NRAS 
and BRAF mutations. The combination of anti-EGFR 
antibodies with first-line chemotherapy increases the 
median OS to 26 months and progression-free sur-
vival (PFS) to 10 months compared to chemotherapy 
(20 months and 8 months, respectively) [8, 9].
The most common side effects of anti-EGFR anti-
bodies are skin reactions caused by disturbed prolifera-
tion, differentiation and migration of keratinocytes as 
well as stimulation of the non-specific immune response 
[10]. Symptoms covering skin and its appendages caused 
by these antibodies are defined as skin toxicity.
Case report
In February 2018, a 55-year-old female patient with 
inoperable recurrence of rectal cancer was admitted to 
the chemotherapy ward to start systemic treatment. The 
malignancy was primary diagnosed in March 2012 when, 
due to gastrointestinal obstruction in the course of rectal 
cancer, a double-barrel sigmoideostomy was performed. 
Due to extension of the disease the patient underwent 
induction chemotherapy with capecitabine (04–07.2012; 
10.2012–03.2013) and after that she received preopera-
tive chemoradiotherapy (07–08.2012). In May 2013, the 
patient underwent laparotomy. Intraoperatively, rectal 
tumour infiltrating the uterus, part of vagina, and the 
anterior abdominal wall was found. As a consequence 
low anterior rectal resection by Hartmann method with 
complete mesorectal resection and hysterectomy was 
performed. In pathological examination tubular adeno-
carcinoma G2 ypT2N0 was diagnosed. In September 
2013, the patient experienced symptoms of mechanical 
gastrointestinal obstruction once again. Intraoperatively, 
intra-abdominal adhesions were found together with the 
intestinal loop drawn into a massive pelvic inflammatory 
infiltration, which was probably a late complication of 
radiation therapy. Ileo-transverse anastomosis was per-
formed. In September 2015, another surgery took place 
due to vaginal-intestinal fistula symptoms. Loops of the 
small intestine were dissected distally from the bypass 
anastomosis, leaving the invaginated stumps.
In November 2017, a positron emission tomogra-
phy (PET) with 18-fluorodeoxyglucose (18-FDG) was 
performed. The recurrence of the disease was found 
in a form of a new lesions — in the bed after complete 
mesorectal resection (SUV max. FDG 5.2) and perito-
neal implants (SUV max. FDG = 6.7).
At admission to the chemotherapy department, the 
patient was in very good general condition PS0 (PS, 
performance status) but slightly underweight (BMI 
18.9, body weight 43 kg). The patient reported pain in 
the anal area and loose stools since the last surgery; 
however, with good appetite, and stable body weight. 
Physical examination revealed the presence of a massive 
hernia in the area of the stoma and numerous, movable 
axillary lymph nodes enlarged to 1 cm. The patient was 
a smoker. She did not report any chronic diseases. The 
family history of cancer was negative. In laboratory tests: 
bone marrow, liver, and kidney functions were normal; 
there were increased values of carcinoembryonic (CEA, 
13.92 ng/mL) and carbohydrate antigen (Ca 19-9 anti-
gen; 43.3 U/mL).
Due to the lack of KRAS, NRAS, and BRAF gene 
mutations and chronic diarrhea, which could poten-
tially be exacerbated by irinotecan, it was decided to 
introduce FOLFOX chemotherapy in combination with 
panitumumab. After the second drug administration 
she developed a G1 acne-like rash on face and torso, 
G2 hand-foot syndrome, and G1 diarrhoea. Oral antibi-
otic therapy with doxycycline at the dose of 2 × 100 mg, 
topical treatment of skin lesions with vitamin A, E and 
cholesterol ointment and loperamide 4 × 4 mg were in-
troduced. After the 4th cycle, the skin lesions intensified 
(G2 rash and G3 hand-foot syndrome), so the topical 
treatment was enriched by 10% urea ointment. After 
the 5th cycle, the patient’s general condition worsened. 
The symptoms of short bowel syndrome connected with 
diarrhoea increased to grade G2 leading to electrolyte 
disturbances. In addition, trophic changes in the abdomi-
nal skin in the area of the stoma (G3) appeared, which 
made considerable difficulties while taking care of it. It 
was necessary to prolong the intervals between infusions 
of cytostatics. Parenteral hydration and correction of 
electrolyte disturbances were introduced simultaneously 
with continuation of current symptomatic treatment. 
Due to the severity of diarrhoea, atropine with diphe-
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noxylate 2.5 mg + 0.025 mg 3 × 2 tablets and morphine 
10 mg every four hours were added to the loperamide 
treatment. A slight improvement was obtained after 
using racecadotril 100 mg three times a day.
First evaluation of treatment effectiveness, based 
on the CT scan, revealed cancer stabilisation. However, 
during this time the patient lost 16% of baseline body 
weight (BMI 15.7), and increased her risk associated 
with nutritional status (NRS, Nutritional Risk Score) 
which was rated 4 — as an indication for nutritional 
treatment. Due to the lack of formal possibilities to 
return to targeted therapy after discontinuation, it 
was decided to continue systemic treatment along with 
symptomatic medications and the use of medical food. 
In subsequent CT scans, disease stabilization main-
tained, but clinically due to exacerbation of skin toxicity 
a temporal brake from panitumumab administration was 
made. Ointments with hydrocortisone (hydrocortisone, 
urea 10%, boric acid 1%) and gentamicin were added to 
symptomatic treatment. Further adverse reactions were 
accompanied by prolonged asymptomatic neutropaenia 
and G2 peripheral polyneuropathy. During the 16th 
oxaliplatin infusion a severe allergic reaction occurred. 
It was manifested by pruritus and redness located on 
the skin of the limbs.
By January 2019, the patient’s PS (PS3) and quality 
of life deteriorated significantly. Because of this and 
due to cachexia and unacceptable toxicity treatment 
was stopped after 16 infusions. For the further care 
the patient was referred to the Oncological Outpatient 
Clinic. In a CT scan performed in March 2019, the 
disease was still stable. The patient died in May 2019, 
without confirmation of cancer progression.
Discussion
Skin toxicity most commonly manifested as acne-like 
rash, periungual inflammation, dryness, and itching of 
the skin occurs in up to 96% of patients receiving pani-
tumumab along with chemotherapy. During FOLFOX 
chemotherapy with panitumumab, skin rash G ≥ 3 was 
observed in 38% of patients, compared to 2% of pa-
tients receiving chemotherapy alone. However, it has 
been shown that there are no significant differences 
in the quality of life of patients depending on whether 
they have G0–2 or G ≥ 3 skin complications [11]. On 
the other hand, the development of G2–4 skin toxicity, 
as opposed to G0–1, correlates with good response to 
treatment. In the first group of patients, higher medians 
of OS and PFS are noted [12–14]. In most patients, 
skin complications disappear during therapy; however, 
in some of them, as in the presented case, they persist 
with significant intensity and may lead to treatment 
discontinuation. 
In this case, skin toxicity was manifested not only as 
a rash characteristic for anti-EGFR drugs, but also as 
dryness and trophic changes of the abdominal skin in 
the area of the stoma and hand-foot syndrome; these 
additional symptoms significantly impaired patient’s 
quality of life. A skin ulceration in the area of the stoma 
made sticking an ostomy pouch impossible, which was 
extremely troublesome due to diarrhoea. In turn, the 
increased hand-foot syndrome worsened patient’s 
daily activities.
Hand-foot syndrome occurs in 6–64% of patients 
treated for cancer, and its frequency depends on the 
type of systemic treatment used. Erythema, oedema, 
hyperkeratosis, and signs of dysesthesia usually occur 
in G1–2 severity. In turn, the G3 degree is associated 
with flaking skin, as well as blistering and ulceration 
accompanied by severe pain that significantly affect 
work and self-service. Hand-foot syndrome is most often 
a complication of capecitabine, liposomal doxorubicin, 
docetaxel, or fluorouracil [15]. In the presented case, 
previous long-term capecitabine chemotherapy was 
likely to affect the appearance and severity of hand-foot 
syndrome. In addition, oxaliplatin exacerbated the 
symptoms of polyneuropathy.
Treatment of skin reactions depends on their severity 
and includes the use of moisturizers, vitamin K oint-
ments, protective skin filters (SPF > 15 UVA and UVB), 
creams containing steroids, and oral antibiotics. If the 
patient develops a G ≥ 3 skin reactions or skin toxicity 
is deemed unacceptable, it is recommended to suspend 
anti-cancer drugs temporarily and, after a restoration, 
continue the therapy in a reduced dose if possible. In 
some patients, the side effects of anti-EGFR drugs dis-
appear only after permanent discontinuation of therapy.
The strategy for management of this skin toxicity 
includes not only treatment but also prophylaxis. Cur-
rently, prophylactic antibiotic therapy with tetracyclines 
or with drugs for external use is not a standard procedure 
because there is no clear evidence of a reduction in skin 
complications frequency. However, there are reports 
that such a modification may not only reduce the risk of 
G2–4 skin toxicity by up to 50% but is also likely to have 
a positive  impact on the quality of life, mainly during 
the initial phase of immunotherapy [16, 17].
Triple-drug therapy with panitumumab is associated 
with higher incidence of G ≥ 3 diarrhoea (18% vs. 9%) 
[12]. Diarrhoea complicating systemic treatment with 
panitumumab is known to be less common in patients 
undergoing prophylactic antibiotic therapy (56% 
vs. 85%), which probably results from anti-inflammatory 
and antibacterial effects of tetracyclines [17].
Numerous anti-diarrhoeal medications were used in 
the presented case, unfortunately with poor therapeutic 
effect. Literature indicates that in the described situation 
some improvement may be achieved by H2 receptor 
329
Kinga Krawiec et al., Short bowel syndrome after panitumumab
blockers or proton pump inhibitors which reduce diar-
rhoea in patients with short bowel syndrome [18]. In the 
presented patient short bowel syndrome was related to 
both current systemic therapy and previous treatment 
consisting of surgeries, chemotherapy, and radiation 
therapy, which led to reduction in length of the intestine 
and impairment of its function. Short bowel syndrome 
is defined as a reduction in the absorption of nutrients 
resulting from excessive shortening or functional dis-
orders of the intestine. It is manifested by debilitating 
diarrhoea, leading to malnutrition and both water and 
electrolyte disorders. Treatment of this syndrome should 
take place in specialist centers. It is based on parenteral 
nutrition with simultaneous enteral nutrition, aimed at 
maintaining the function of intestine and preventing 
atrophy of the intestinal villi.
Limited availability of outpatient clinics that spe-
cialize in nutritional treatment is a hindrance to cancer 
patients. Modification of therapy by adding adequate 
nutritional treatment is bound to improve the general 
condition of the patients in whom short bowel syndrome 
led to cachexia and abandoning chemotherapy.
It is estimated that as many as 10–20% of cancer 
patients die due to malnutrition, and only 30–60% of 
the ones at risk receive nutritional support (i.e. oral sup-
plements or parenteral nutrition or enteral nutrition). 
One of the European multicenter studies estimated 
that nearly 40% of cancer patients receive incorrect 
classification of nutrition level, resulting in the lack of 
adequate nutritional intervention [19].
According to the guidelines of the European Socie-
ty for Clinical Nutrition and Metabolism (ESPEN), 
long-term parenteral nutrition should be offered in 
bowel failure if: 1) enteral nutrition is insufficient, 2) 
the predicted survival is longer than 2–3 months, 3) it 
is anticipated that parenteral nutrition may stabilise 
or improve the patient’s performance status and qual-
ity of life [20]. In addition, BMI in the range of 18.5– 
–20.0 kg/m2 means the patient is at the risk of malnutri-
tion with an indication for the introduction of nutritional 
treatment. BMI below 18.5 kg/m2 is diagnosed as malnu-
trition with the need for urgent nutritional intervention.
Anti-EGFR monotherapy is less likely to cause 
life-threatening complications in comparison with 
chemotherapy. However, cumulative toxicity coming 
from combination of targeted drugs and chemotherapy 
may impair the quality of life in a significant way. More-
over it may create the need for dose reduction or drug 
discontinuation which in turn reduces the chances of 
obtaining desired therapeutic effects. In Poland, cetuxi-
mab and panitumumab treatment is financed under the 
Ministry of Health’s drug program. If the antibody used 
in the first line is discontinued due to toxicity, the drug 
program does not allow its re-use in the third line even 
if its ineffectiveness has not been proven. Updated drug 
program (Novemeber 2019) allows for interruption in 
cytotoxic treatment but interval between antibody infu-
sions can not be longer than 8 weeks. In this regard, it 
is extremely important to carry out a proper qualifica-
tion before  administration of triple therapy  including 
anti-EGFR antibodies.
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